The Endocrine Society is collecting information from NIH-funded researchers to understand what barriers our members are having in receiving funding. We want to make sure Congress understands what barriers there are. If you are an NIH-funded researcher, please fill out this brief form to provide us with information on the status of your grant funding.
On April 30, the US Senate Appropriations Committee conducted a bipartisan hearing on "Biomedical Research: Keeping America's Edge in Innovation." Four biomedical research organizations and a mother and patient advocate provided testimony on the need to prevent cuts to funding for the National Institutes of Health and protect the United States’ leadership of the biomedical research enterprise. Chair Susan Collins (R-ME) and Ranking Member Patty Murray (D-WA) were both critical of the administration’s attempts to cut biomedical research funding, expressing how cuts would threaten the health of the public and the economy.
“If clinical trials are halted, research is stopped, and laboratories are closed, effective treatments and cures for diseases like Alzheimer’s, Type I diabetes, childhood cancers, and Duchenne’s Muscular Dystrophy, will be delayed or not discovered at all,” said Senator Collins in her opening statement.
As part of the Endocrine Society’s advocacy efforts to protect biomedical research funding, the Society submitted a statement for the record and joined with other leading women’s health organizations to submit a letter urging Congress to protect funding for women’s health research. If you are a researcher based in the United States, take action through our campaign to tell Congress to protect NIH funding.
Together with the European Society for Endocrinology (ESE) and the European Society for Paediatric Endocrinology (ESPE), the Endocrine Society submitted a statement to an expert group comprising representatives from EU Member States as well as public interest organizations who advise the EU on chemicals legislation and policy. In our statement, we expressed support for the introduction of a provision to account for the effects of exposure to multiple chemicals, and the wider application of a hazard-based approach to endocrine-disrupting chemicals (EDCs) based on their intrinsic properties, in both categories of the revised Regulation for Classification, Labelling and Packaging of substances and mixtures (CLP Regulation) and the promotion of grouping approaches to address regrettable substitutions. We look forward continuing to inform the debate within the expert group in the months to come and lay the foundation for an ambitious revision of chemicals legislation that will effectively address the health and environment hazards caused by EDCs.
We rely on your voice to advocate for our policy priorities. Join us to show our strength as a community that cares about endocrinology. Contact your US representatives or European Members of Parliament through our online platform. Take action and make a difference today.
